猿猿之程序员
07-28
$同源康医药-B(02410)$
区别于哌柏西利,特异性靶向CDK4/6-cyclin D1界面,同源康的竟争格局还是有优势的
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":461479399428136,"tweetId":"461479399428136","gmtCreate":1753684053388,"gmtModify":1753684057953,"author":{"id":3564011840073775,"idStr":"3564011840073775","authorId":3564011840073775,"authorIdStr":"3564011840073775","name":"猿猿之程序员","avatar":"https://static.tigerbbs.com/a37cb08394c3dc27fb59f07921d7c74f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a><span>区别于哌柏西利,特异性靶向CDK4/6-cyclin D1界面,同源康的竟争格局还是有优势的</span></body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a><span>区别于哌柏西利,特异性靶向CDK4/6-cyclin D1界面,同源康的竟争格局还是有优势的</span></body></html>","text":"$同源康医药-B(02410)$ 区别于哌柏西利,特异性靶向CDK4/6-cyclin D1界面,同源康的竟争格局还是有优势的","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/461479399428136","repostId":0,"isVote":1,"tweetType":1,"viewCount":412,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":96,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/461479399428136"}
精彩评论